GlassScriptPhysician profile
Farzana Aziz
NPI 1841453057
$3,025.45
in general payments reported to CMS, 2019-2025
33 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $388 · 2021: $584 · 2022: $390 · 2023: $558 · 2024: $257 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $767.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $409.92 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $197.99 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $179.35 | 2019-2024 | Gardasil 9, Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $139.31 | 2019-2025 | |
| Thd America, INC. | $133.07 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $129.80 | 2019-2022 | |
| Amarin Pharma, INC. | $105.34 | 2019-2021 | |
| Abbvie INC. | $102.26 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.91 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $84.11 | 2020-2023 | Xarelto |
| Boston Scientific Corporation | $59.41 | 2023 | |
| Amgen INC. | $58.54 | 2021-2025 | Tezspire |
| Exact Sciences Corporation | $52.85 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $52.27 | 2024-2025 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $51.25 | 2019-2020 | |
| Glaxosmithkline, LLC. | $42.01 | 2019-2024 | Nucala |
| E.R. Squibb & Sons, L.L.C. | $34.78 | 2023 | Eliquis |
| Almatica Pharma LLC | $28.29 | 2025 | Teriparatide |
| Sumitomo Pharma America, INC. | $27.37 | 2023 | Gemtesa |
| Vertex Pharmaceuticals Incorporated | $26.59 | 2025 | |
| Advanced Respiratory, INC | $24.86 | 2019 | |
| Sunovion Pharmaceuticals INC. | $24.84 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.03 | 2025 | Rexulti |
| Abbott Laboratories | $23.85 | 2021 | |
| Mylan Specialty L.P. | $23.56 | 2023 | Yupelri |
| Verona Pharma, INC. | $22.85 | 2025 | Ohtuvayre |
| Dynavax Technologies Corporation | $20.46 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.68 | 2025 | |
| Esperion Therapeutics, INC. | $17.10 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.63 | 2019 | |
| Daiichi Sankyo INC. | $15.63 | 2023 | Injectafer |
| Philips North America LLC | $14.65 | 2024 | (Ck7) Extended Holter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farzana Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.